BRISBANE, Calif., May 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve
Porter, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at the 2010 Citi Health Care Conference in New York on May 26 at
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY). A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 or ITMN-191, partnered by Roche) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
SOURCE InterMune, Inc.
Subscribe to our Free Newsletters!
Boosting metabolism is what you might need to pump your weight loss regime. Slow body metabolism ...
Telemedicine is a rapidly growing field aimed at providing health and clinical services remotely ...
Turmeric is an age-old herb which has medicinal properties. Turmeric added to milk offers a wide ...View All